Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 441-446

  O'Doherty, B ^a   Daniel, R ^b  

^a Gorey Co   (Ireland)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031750980     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691580     Document Type: Article

References (11)

1. Fromtling RA, Castañer J: Trovafloxacin mesylate. Drugs of the Future (1996) 21:496-505
2. Gootz TD, Brighty KE: Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews (1996) 16:433-486
3. Klugman KP, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:878-880
4. Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy (1995) 35:230-232
5. Jones RN: In vitro antimicrobial activity of CP-99,219, a new 7-azabicylonaphthyridone. Drugs (1995) 49, Supplement 2:205-207
6. Crokaert F, Aoun M, Duchateau V, Grenier P, Rossi C, Vandermies A, Klastersky J: In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:696-698
7. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE: Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy (1995) 36:385-394
8. Teng R, Liston TE, Harris SC: Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy (1996) 37:955-963
9. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine (1987) 106:196-204
10. Nicotra MB, Rivera M, Awe RJ: Antibiotic therapy of acute exacerbation of chronic bronchitis. Annals of Internal Medicine (1982) 97:18-20
11. Bates JM: The role of infection during exacerbation of chronic bronchitis. Annals of Internal Medicine (1982) 97:130-131